We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Viatris (VTRS) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Viatris (VTRS - Free Report) closed at $14.36 in the latest trading session, marking a -1.17% move from the prior day. This move lagged the S&P 500's daily gain of 0.28%. Elsewhere, the Dow gained 0.29%, while the tech-heavy Nasdaq added 0.16%.
Prior to today's trading, shares of the generic drugmaker had gained 6.6% over the past month. This has outpaced the Medical sector's loss of 9.62% and the S&P 500's loss of 5.39% in that time.
Viatris will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $0.82, down 12.77% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $4.31 billion, up 19.03% from the year-ago period.
Any recent changes to analyst estimates for Viatris should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Viatris is currently sporting a Zacks Rank of #4 (Sell).
Digging into valuation, Viatris currently has a Forward P/E ratio of 3.94. For comparison, its industry has an average Forward P/E of 22.85, which means Viatris is trading at a discount to the group.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 197, which puts it in the bottom 23% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Viatris (VTRS) Stock Sinks As Market Gains: What You Should Know
Viatris (VTRS - Free Report) closed at $14.36 in the latest trading session, marking a -1.17% move from the prior day. This move lagged the S&P 500's daily gain of 0.28%. Elsewhere, the Dow gained 0.29%, while the tech-heavy Nasdaq added 0.16%.
Prior to today's trading, shares of the generic drugmaker had gained 6.6% over the past month. This has outpaced the Medical sector's loss of 9.62% and the S&P 500's loss of 5.39% in that time.
Viatris will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $0.82, down 12.77% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $4.31 billion, up 19.03% from the year-ago period.
Any recent changes to analyst estimates for Viatris should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Viatris is currently sporting a Zacks Rank of #4 (Sell).
Digging into valuation, Viatris currently has a Forward P/E ratio of 3.94. For comparison, its industry has an average Forward P/E of 22.85, which means Viatris is trading at a discount to the group.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 197, which puts it in the bottom 23% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.